{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:27:12Z","timestamp":1760016432854},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,1,26]],"date-time":"2013-01-26T00:00:00Z","timestamp":1359158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s40256-013-0006-7","type":"journal-article","created":{"date-parts":[[2013,1,25]],"date-time":"2013-01-25T04:09:58Z","timestamp":1359086998000},"page":"17-25","source":"Crossref","is-referenced-by-count":7,"title":["Tolerability and Pharmacokinetics of Ranolazine Following Single and Multiple Sustained-release Doses in Chinese Healthy Adult Volunteers"],"prefix":"10.1007","volume":"13","author":[{"given":"Qin-You","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan-De","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Hua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-Zhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Xing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,1,26]]},"reference":[{"issue":"1","key":"6_CR1","first-page":"131","volume":"20","author":"G Cocco","year":"1992","unstructured":"Cocco G, Rousseau MF, Bouvy T, et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol. 1992;20(1):131\u20138.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"6_CR2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0002-8703(03)00256-4","volume":"146","author":"SC Beinart","year":"2003","unstructured":"Beinart SC, Sales AE, Spertus JA, et al. Impact of angina burden and other factors on treatment satisfaction after acute coronary syndromes. Am Heart J. 2003;146(4):646\u201352.","journal-title":"Am Heart J"},{"issue":"8","key":"6_CR3","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","volume":"43","author":"BR Chaitman","year":"2004","unstructured":"Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8):1375\u201382.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"6_CR4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.amjcard.2004.09.025","volume":"95","author":"MF Rousseau","year":"2005","unstructured":"Rousseau MF, Pouleur H, Cocco G, et al. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. 2005;95(3):311\u20136.","journal-title":"Am J Cardiol"},{"key":"6_CR5","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1161\/CIRCULATIONAHA.105.597500","volume":"113","author":"BR Chaitman","year":"2006","unstructured":"Chaitman BR. Ranolazine for the treatment of chronic angia and potential use in other cardiovascular conditions. Circulation. 2006;113:2462\u201372.","journal-title":"Circulation"},{"key":"6_CR6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/eurheartj\/ehi624","volume":"27","author":"R Cooper-DeHoff","year":"2006","unstructured":"Cooper-DeHoff R, Pepine CJ. Ranolazine is associated with cardiovascular and metabolic improvement: a win-win for patients with diabetes. Eur Heart J. 2006;27:5\u20136.","journal-title":"Eur Heart J"},{"key":"6_CR7","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.0000139333.83620.5D","volume":"110","author":"C Antzelevitch","year":"2004","unstructured":"Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110:904\u201310.","journal-title":"Circulation"},{"issue":"2","key":"6_CR8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/00005344-200408000-00008","volume":"44","author":"Y Song","year":"2004","unstructured":"Song Y, Shryock JC, Wu L, et al. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 2004;44(2):192\u20139.","journal-title":"J Cardiovasc Pharmacol"},{"key":"6_CR9","doi-asserted-by":"crossref","first-page":"I3","DOI":"10.1016\/S1520-765X(04)80002-6","volume":"6","author":"L Belardinelli","year":"2004","unstructured":"Belardinelli L, Antzelevitch C, Fraser H. Inhibition of late (sustained\/persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J Suppl I. 2004;6:I3\u20137.","journal-title":"Eur Heart J Suppl I"},{"issue":"8","key":"6_CR10","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.hrthm.2011.03.045","volume":"8","author":"C Antzelevitch","year":"2011","unstructured":"Antzelevitch C, Burashnikov A, Sicouri S, et al. Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm. 2011;8(8):1281\u201390.","journal-title":"Heart Rhythm"},{"issue":"1","key":"6_CR11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/jssc.200500174","volume":"29","author":"X Luo","year":"2006","unstructured":"Luo X, Zhai Z, Wu X, et al. Analytical and semipreparative resolution of ranolazine enantiomers by liquid chromatography using polysaccharide chiral stationary phases. J Sep Sci. 2006;29(1):164\u201371.","journal-title":"J Sep Sci"},{"issue":"1","key":"6_CR12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0021-9673(95)00475-3","volume":"712","author":"WJ Herron","year":"1995","unstructured":"Herron WJ, Eadie J, Penman AD. Estimation of ranolazine and eleven phase I metabolites in human plasma by liquid chromatography-atmospheric pressure chemical ionisation mass spectrometry with selected-ion monitoring. J Chromatogr A. 1995;712(1):55\u201360.","journal-title":"J Chromatogr A"},{"issue":"4","key":"6_CR13","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/rcm.2331","volume":"20","author":"Y Liang","year":"2006","unstructured":"Liang Y, Xie L, Liu XD, et al. Simple, sensitive and rapid liquid chromatography\/atmospheric pressure chemical ionization mass spectrometric method for the quantitation of Ranolazine in rat plasma. Rapid Commun Mass Spectrom. 2006;20(4):523\u20138.","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"3","key":"6_CR14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1365\/s10337-005-0712-7","volume":"63","author":"J Zhong","year":"2006","unstructured":"Zhong J, Liu XQ, Chen Y, Zhao XP, et al. Determination of ranolazine in rat plasma by liquid chromatography-electrospray ionization mass spectrometry. Chromatographia. 2006;63(3):123\u20137.","journal-title":"Chromatographia"},{"issue":"10","key":"6_CR15","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.clinthera.2007.10.005","volume":"29","author":"Y Li","year":"2007","unstructured":"Li Y, Jiang X, Lan K, et al. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: A randomized open-label, three-way crossover study. Clin Ther. 2007;29(10):2194\u2013203.","journal-title":"Clin Ther"},{"issue":"5","key":"6_CR16","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jpba.2008.09.033","volume":"48","author":"U Bhaumik","year":"2008","unstructured":"Bhaumik U, Ghosh A, Sarkar AK, et al. Determination of ranolazine in human plasma by LC\u2013MS\/MS and its application in bioequivalence study. J Pharm Biomed Anal. 2008;48(5):1404\u201310.","journal-title":"J Pharm Biomed Anal"},{"key":"6_CR17","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2165\/00003088-200645050-00003","volume":"45","author":"Markus Jerling","year":"2006","unstructured":"Jerling Markus. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet. 2006;45:469\u201391.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"6_CR18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF03190499","volume":"28","author":"XD Liu","year":"2003","unstructured":"Liu XD, Xie L, Liang Y, et al. Gender difference in ranolazine pharmacokinetics in rats. Eur J Drug Metab Pharmacokinet. 2003;28(2):119\u201323.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"6_CR19","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clpt.2005.05.004","volume":"78","author":"M Jerling","year":"2005","unstructured":"Jerling M, Abdallah H. Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine. Clin Pharmacol Ther. 2005;78(3):288\u201397.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"6_CR20","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1345\/aph.1P297","volume":"44","author":"DA Pierce","year":"2010","unstructured":"Pierce DA, Reeves-Daniel AM. Ranolazine-tacrolimus interaction. Ann Pharmacother. 2010;44(11):1844\u20139.","journal-title":"Ann Pharmacother"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-013-0006-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-013-0006-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-013-0006-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:28:24Z","timestamp":1559489304000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-013-0006-7"}},"subtitle":["A Randomized, Open-label, Latin Square Design, Phase I Study"],"short-title":[],"issued":{"date-parts":[[2013,1,26]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["6"],"URL":"https:\/\/doi.org\/10.1007\/s40256-013-0006-7","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,26]]}}}